Alternatively, CD40 antibodies have been combined with IL-2 immunotherapy as a strategy to induce tumor-specific T cell immunity in tumor models of renal cell adenocarcinoma or Lewis lung carcinoma. This evidence concerns the gene CD40 and neoplasm.